Ascelia Pharma AB (publ) (ticker: ACE), hereby invites analysts, investors and media to its investor update on Tuesday March 14, 2023 at 14:00. Focus of the event will be on bringing Orviglance to market – next steps towards launch.
Live Q&A webcast
The event consists of presentations from Ascelia Pharma executives followed by a live Q&A webcast. The presentations will be available on Ascelia Pharma’s website www.ascelia.com on March 14 at 08:00 a.m. CET.
The livestreamed Q&A webcast with will take place on March 14 from 14:00 CET. A recording of the Q&A webcast will be published on Ascelia Pharma’s website after the event.
All presentations will be held in English.
Orviglance in focus
Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A pivotal clinical program of nine studies, including the global Phase 3 study SPARKLE, have been completed. Headline results from the Phase 3 study are expected mid-2023.
Registration for the live Q&A webcast
Participation for the live Q&A webcast can register by contacting Ascelia Pharma’s Executive Assistant Delphine Biro at db@ascelia.com. Please confirm your participation no later than March 14, 2023.